Forum Topic News
  • Conversation: Vertex to test CF triple combo therapy in Phase III trials

    • April 27, 2018 12:57 PM BST
    • Vertex to test CF triple combo therapy in Phase III trials

      Vertex Pharmaceuticals will begin testing a combination of VX-445, tezacaftor and ivacaftor as a potential treatment for people with cystic fibrosis (CF) in two Phase III studies.
      The first trial will evaluate the combination in around 360 people with CF who have one copy of the F508del mutation and one minimal function mutation, and is designed to support the submission of a New Drug Application (NDA) in the US.
      The second will include around 100 CF patients who have two copies of the F508del mutation, the most common genetic form of the disease, and is also designed to support submission of an application for this subset in the US, Vertex said.
      Read more: http://www.pharmatimes.com/news/vertex_to_test_cf_triple_combo_therapy_in_phase_iii_trials_1233503

Add Reputation

Do you want to add reputation for this member by this post?

or cancel
‚Äč